LadRx Corporation highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the maytansinoid-based drug delivery systems. First-generation LADR-based drug candidate, Aldoxorubicin, has been out-licensed to Immunity Bio Inc. and is in clinical trials for pancreatic cancer. Next-generation LADR-based drug candidates employ an improved linker and highly potent chemotherapeutic agents. The Company's pre-clinical drug candidates are based on this next-gen LADR design, namely LADR7-10.

LADR7 and 8 employ the highly potent chemotoxin Auristatin E, while LADR9 and 10 employ another highly potent chemotoxin called Maytansine. LADR7-10 have demonstrated powerful anti-cancer activity in pre-clinical animal models in several different types of solid tumors, and have shown acceptable toxicity profiles. These compounds are positioned to move into IND-enabling activities, and could be IND-ready and into Phase 1 clinical trials in as little as 18 months from funding of the LADR program.